Immune Checkpoint PD-1/PD-L1: Is There Life Beyond Antibodies?

被引：113

作者：

Konstantinidou, Markella ^{[1
]}

Zarganes-Tzitzikas, Tryfon ^{[1
]}

Magiera-Mularz, Katarzyna ^{[2
]}

Holak, Tad A. ^{[2
,3
]}

Domling, Alexander ^{[1
]}

机构：

[1] Univ Groningen, Dept Drug Design, A Deusinglaan 1, NL-9713 AV Groningen, Netherlands

[2] Jagiellonian Univ, Fac Chem, Ingardena 3, PL-30060 Krakow, Poland

[3] Max Planck Inst Biochem, Klopferspitz 18a, D-82152 Martinsried, Germany

来源：

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION | 2018年 / 57卷 / 18期

基金：

新加坡国家研究基金会;

关键词：

antitumor agents; protein-protein interactions; PD-1; PD-L1; protein structures; PROGRAMMED DEATH-1; STRUCTURAL BASIS; CANCER-IMMUNOTHERAPY; CRYSTAL-STRUCTURE; HUMAN PD-1; CELL; INHIBITORS; BLOCKADE; LIGANDS; COMPLEX;

D O I：

10.1002/anie.201710407

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

The PD-1/PD-L1 interaction has emerged as a significant target in cancer immunotherapy. Current medications include monoclonal antibodies, which have shown impressive clinical results in the treatment of several types of tumors. The cocrystal structure of human PD-1 and PD-L1 is expected to be a valuable starting point for the design of novel inhibitors, along with the recent crystal structures with monoclonal antibodies, small molecules, and macrocycles.

引用

页码：4840 / 4848

页数：9

共 50 条

[41] INTRATUMORAL EXPRESSION OF PD-1/PD-L1 IMMUNE CHECKPOINT IN PATIENTS WITH HEPATOCELLULAR CARCINOMA
Baquerizo, Angeles
Vavinskaya, Vera
Rojas, Angela
Mhoyan, Anna
Romero-Gomez, Manuel
Sher, Linda
Madani, Bahar
Fisher, Jonathan
Schaffer, Randolph
Frenette, Catherine T.
Marsh, Christopher
HEPATOLOGY, 2019, 70 : 206A - 206A
[42] Investigation of the status of immune checkpoint molecules (PD-L1 and PD-1) in meningiomas by immunohistochemistry
Saygin, Ismail
Cakir, Emel
Kazaz, Seher Nazli
Guvercin, Ali Riza
Eyupoglu, Ilker
Ustaoglu, Muserref Muge
TURKISH JOURNAL OF MEDICAL SCIENCES, 2024, 54 (04)
[43] Cancer immunotherapy and the PD-1/PD-L1 checkpoint pathway
Barclay, Jonathan
Creswell, Joanne
Leon, Juan
ARCHIVOS ESPANOLES DE UROLOGIA, 2018, 71 (04): : 393 - 399
[44] Structural basis of PD-1/PD-L1 checkpoint inhibition
Magiera, K.
Zak, K.
Berlicki, L.
Domling, A.
Holak, T.
Dubin, G.
FEBS JOURNAL, 2017, 284 : 45 - 45
[45] PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
Liu, Jinhua
Chen, Zichao
Li, Yaqun
Zhao, Wenjie
Wu, JiBiao
Zhang, Zhen
FRONTIERS IN PHARMACOLOGY, 2021, 12
[46] Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies
Sibaud, Vincent
Meyer, Nicolas
Lamant, Laurence
Vigarios, Emmanuelle
Mazieres, Julien
Delord, Jean Pierre
CURRENT OPINION IN ONCOLOGY, 2016, 28 (04) : 254 - 263
[47] Immune checkpoint inhibition in myeloid malignancies: Moving beyond the PD-1/PD-L1 and CTLA-4 pathways
Bewersdorf, Jan Philipp
Shallis, Rory M.
Zeidan, Amer M.
BLOOD REVIEWS, 2021, 45
[48] Targeting the host immune system: PD-1 and PD-L1 antibodies and breast cancer
Dawood, Shaheenah
Rugo, Hope S.
CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE, 2016, 10 (04) : 336 - 342
[49] Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2
Zak, Krzysztof M.
Grudnik, Przemyslaw
Magiera, Katarzyna
Domling, Alexander
Dubin, Grzegorz
Holak, Tad A.
STRUCTURE, 2017, 25 (08) : 1163 - 1174
[50] Tackling Immune Targets for Breast Cancer: Beyond PD-1/PD-L1 Axis
Tabana, Yasser
Okoye, Isobel S.
Siraki, Arno
Elahi, Shokrollah
Barakat, Khaled H.
FRONTIERS IN ONCOLOGY, 2021, 11

← 1 2 3 4 5 →